(19)
(11) EP 1 294 711 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
08.03.2006 Bulletin 2006/10

(45) Mention of the grant of the patent:
07.12.2005 Bulletin 2005/49

(21) Application number: 01937687.0

(22) Date of filing: 24.05.2001
(51) International Patent Classification (IPC): 
C07D 403/06(1990.01)
A61P 43/00(2000.01)
 A61K 31/404(2000.01)
(86) International application number:
PCT/US2001/016756
(87) International publication number:
WO 2001/090104 (29.11.2001 Gazette 2001/48)

(54)

1-(PYRROLIDIN-1-YLMETHYL)-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN KINASES

1-(PYRROLIDIN-1-YLMETHYL)-3-(PYRROL-2-YLMETHYLIDEN)-2-INDOLINON DERIVATE UND DEREN VERWENDUNG ALS PROTEIN KINASE INHIBITOREN

DERIVES DE 1-(PYRRLOLIDIN-1-YLMETHYL)-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 24.05.2000 US 207000 P
11.08.2000 US 225045 P

(43) Date of publication of application:
26.03.2003 Bulletin 2003/13

(73) Proprietor: Pharmacia & Upjohn Company LLC
Kalamazoo, MI 49001 (US)

(72) Inventors:
  • MOON, Malcolm, Wilson
    Kalamazoo, MI 49004 (US)
  • MOROZOWICH, Walter
    Kalamazoo, MI 49004 (US)
  • GAO, Ping
    Portage, MI 49024 (US)

(74) Representative: Viering, Hans-Martin 
Patent- und Rechtsanwälte Viering, Jentschura & Partner, Steindorfstrasse 6
80538 München
80538 München (DE)


(56) References cited: : 
WO-A-00/08202
WO-A-99/61422
 WO-A-01/90068
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).